Literature DB >> 1370552

p53 mutations are not selected for in simian virus 40 T-antigen-induced tumors from transgenic mice.

M Moore1, A K Teresky, A J Levine, M Seiberg.   

Abstract

Many diverse tumors contain cells that select for mutations at the p53 gene locus. This appears to be the case because the p53 gene product can act as a negative regulator of cell division or a tumor suppressor. These mutations then eliminate this activity of the p53 gene product. The simian virus 40 (SV40) large T antigen binds to p53 and acts as an oncogene to promote cellular transformation and initiate tumors. If the binding of T antigen to the p53 protein inactivated its tumor suppressor activity, there would be no selection pressure for p53 mutants to appear in tumors. To test this idea, transgenic mice that carried and expressed the SV40 large T-antigen gene were created. Expression of the T antigen was directed to the liver, using the albumin promoter, and the choroid plexus, using the SV40 enhancer-promoter. A large number of papillomas (indicated in parentheses) of the choroid plexus (14), hepatocellular carcinomas (5), liver adenomas (10), and tumors of clear-cell foci (5) were examined for mutant and wild-type p53 genes and gene products. In all cases, the tumor extracts contained readily detectable T-antigen-p53 protein complexes. A monoclonal antibody specifically recognizing the wild-type p53 protein (PAb246) reacted with p53 in every tumor extract. A monoclonal antibody specifically recognizing mutant forms of the p53 protein (PAb240) failed to detect p53 antigens in these extracts. Finally, p53 partial cDNAs were sequenced across the regions of common mutations in this gene, and in every case only the wild-type sequence was detected. These results strongly support the hypothesis that T antigen inactivates the wild-type p53 tumor-suppressing activity and there is no need to select for mutations at the p53 locus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370552      PMCID: PMC240762     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Cooperation of SV40 large T antigen and the cellular protein p53 in maintenance of cell transformation.

Authors:  W Deppert; T Steinmayer; W Richter
Journal:  Oncogene       Date:  1989-09       Impact factor: 9.867

2.  SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene.

Authors:  J A DeCaprio; J W Ludlow; J Figge; J Y Shew; C M Huang; W H Lee; E Marsilio; E Paucha; D M Livingston
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

3.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

4.  Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product.

Authors:  P Whyte; K J Buchkovich; J M Horowitz; S H Friend; M Raybuck; R A Weinberg; E Harlow
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

5.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.

Authors:  B Bressac; M Kew; J Wands; M Ozturk
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

6.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.

Authors:  D Hanahan
Journal:  Nature       Date:  1985 May 9-15       Impact factor: 49.962

7.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.

Authors:  N Dyson; P M Howley; K Münger; E Harlow
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

8.  Cellular gene expression in papillomas of the choroid plexus from transgenic mice that express the simian virus 40 large T antigen.

Authors:  J R Marks; J Lin; P Hinds; D Miller; A J Levine
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

9.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

Authors:  L F Parada; H Land; R A Weinberg; D Wolf; V Rotter
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

10.  T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein/SV40 T antigen hybrid gene.

Authors:  W A Held; J J Mullins; N J Kuhn; J F Gallagher; G D Gu; K W Gross
Journal:  EMBO J       Date:  1989-01       Impact factor: 11.598

View more
  6 in total

1.  A subset of cells expressing SV40 large T antigen contain elevated p53 levels and have an altered cell cycle phenotype.

Authors:  T L Sladek; J Laffin; J M Lehman; J W Jacobberger
Journal:  Cell Prolif       Date:  2000-04       Impact factor: 6.831

2.  Transgenic hepatocarcinogenesis in the rat.

Authors:  J R Hully; Y Su; J K Lohse; A E Griep; C A Sattler; M J Haas; Y Dragan; J Peterson; M Neveu; H C Pitot
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

3.  Neuroepithelial carcinomas in mice transgenic with human papillomavirus type 16 E6/E7 ORFs.

Authors:  J M Arbeit; K Münger; P M Howley; D Hanahan
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

4.  Transgenic mice support replication of hepatitis delta virus RNA in multiple tissues, particularly in skeletal muscle.

Authors:  J M Polo; K S Jeng; B Lim; S Govindarajan; F Hofman; F Sangiorgi; M M Lai
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

5.  SV40 Tag DNA sequences, present in a small proportion of human hepatocellular carcinomas, are associated with reduced survival.

Authors:  N A C S Wong; F Rae; M M Herriot; N J Mayer; D H Brewster; D J Harrison
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

6.  Transgenic mouse models that explore the multistep hypothesis of intestinal neoplasia.

Authors:  S H Kim; K A Roth; A R Moser; J I Gordon
Journal:  J Cell Biol       Date:  1993-11       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.